'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China

Next-Stage Strategies Formulated

Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.

China flag and syringe
MNCs want to sit in driver's seat in Changing China • Source: Shutterstock

Since China performed a sudden and drastic U-turn and dismantled most of its restrictive policies related to COVID-19 late last year, biopharma companies are embracing a unique opportunity to catch up but also regain growth in the country. Recent moves show how deeper and localized approaches are being pursued by major health sector players.

Top executives from multinationals from Pfizer Inc. to AstraZeneca PLC and Roche Holding AG say that being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia